Jan 8 (Reuters) - Health insurer Anthem Inc on Thursday said it reached a
deal under which Gilead Sciences Inc's hepatitis C drug Harvoni will be the
primary treatment for patients infected with the most common strain of the
liver-destroying virus.
Anthem said the deal effectively lowers its hepatitis C treatment costs. "We
were able to achieve a very competitive rate and a freeze on retail pricing
for 2015," the insurer said in an emailed statement. "That does favorably
impact plan costs for 2015."
